Results 111 to 120 of about 31,037 (228)
Movement Disorders, EarlyView.Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota +14 more
wiley +1 more source
UK Medical Cannabis Registry: A Two-Year Prospective Observational Cohort Study of Clinical Outcomes in Insomnia. [PDF]
Neuropsychopharmacol RepInsomnia affects around one in ten adults. In this 2‐year UK Medical Cannabis Registry cohort study of 211 adults with insomnia, treatment with cannabis‐based medicinal products was associated with a sustained improvement in self‐reported sleep quality across 24 months.
Koye A +7 more
europepmc +2 more sources
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies
Medicinal Research Reviews, EarlyView.ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva +23 more
wiley +1 more source
Cannabinoids in neurology – Brazilian Academy of Neurology
Arquivos de Neuro-Psiquiatria, 2015 The use of cannabidiol in some neurological conditions was allowed by Conselho Regional de Medicina de São Paulo and by Agência Nacional de Vigilância Sanitária (ANVISA).
Sonia M. D. Brucki +12 more
doaj +1 more source
Phytotherapy Research, EarlyView.ABSTRACT The use of medicinal products derived from cannabis and its synthetic analogues has grown in recent years for various health conditions, which led to an increase in systematic reviews (SR) on the topic. The objective of this overview was to identify, synthesize, and critically appraise the evidence from SR on the benefits and harms of cannabis
Rafael Leite Pacheco +5 more
wiley +1 more source
Cannabidiol Toxicity Driven by Hydroxyquinone Formation [PDF]
Oxidative byproducts of cannabidiol (CBD) are known to be cytotoxic. However, CBD susceptibility to oxidation and resulting toxicity dissolved in two common solvents, ethanol (EtOH) and dimethyl sulfoxide (DMSO), is seldom discussed.
Rajaram, Pravien S +5 more
core +1 more source
Veterinary Record, EarlyView.Abstract Background Osteoarthritis (OA) causes chronic pain and reduces welfare in dogs. Standard treatments may be inadequate or associated with adverse effects, prompting investigation of alternative therapies. Transcutaneous electrical nerve stimulation (TENS) is a non‐pharmacological pain management method, but evidence for its efficacy in canine ...
Anja Pedersen +5 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer +16 more
wiley +1 more source
Addiction, EarlyView.Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka +6 more
wiley +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source